$ATAI

HERSHBERG ROBERT sold $496K of ATAI

HERSHBERG ROBERT sold 100,000 shares of AtaiBeckley Inc. (ATAI) at $4.96 ($0.50M total) on 2026-07-07 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · HERSHBERG ROBERT
Published Jul 9, 2026, 9:30 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Jul 9, 2026, 9:34 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$ATAI
Neutral
high confidence
Mentioned
$ATAI
Relevance
3/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$ATAINeutralLow
01

Why it matters

This is a disclosed insider transaction with no accompanying new corporate event (no earnings, trial result, guidance, or deal). The main tradable element is potential sentiment around insider selling, tempered by the stated 10b5-1 plan.

02

Market read

Traders may note the sale for sentiment, but it is unlikely to change valuation without additional fundamental catalysts.

03

What to watch

The article does not state whether other insiders or the company have concurrent transactions, nor does it provide context on total holdings or prior sale cadence.

Relevance 3/10Novelty 2/10Timing: Filed 2026-07-09 after-hours; reflects sale executed 2026-07-07.

Background

The article is a SEC Form 4 disclosure of an insider open-market sale by a director of AtaiBeckley Inc.

Company-level read

Ticker impact

$ATAINeutralHigh confidence
Context

AtaiBeckley director Robert Hershberg sold 100,000 shares at $4.96 on 2026-07-07 under a pre-arranged 10b5-1 plan.

Expected impact

Likely limited, short-lived impact; any move would be more sentiment-driven than fundamental.

Evidence & confidence

The filing is a Form 4 insider transaction, explicitly tied to a pre-arranged 10b5-1 plan, and provides no new company-specific performance or guidance data.

Market effects

Minimal read-across to biotech sector fundamentals; this is an individual insider liquidity event.

None indicated.

None indicated.

Counterpoint

Because the sale is under a 10b5-1 plan, it may not signal bearish expectations and could be interpreted as planned diversification rather than concern.

Key entities

  • AtaiBeckley Inc.

    Subject of the Form 4 insider transaction disclosure.

  • Hershberg Robert

    Director who sold 100,000 shares under a pre-arranged 10b5-1 plan.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$LLYMedAI 8/10

$35 Billion Frog Drug Deal Explained: The Psychedelic Treatment That Could Change Depression Therapy

Eli Lilly is reportedly investing $35 billion in ATAI Life Sciences' psychedelic drug BPL-003, derived from a compound found in the Sonoran Desert toad, for treating depression. Clinical trials showed improvements in treatment-resistant depression patients, but long-term effects are still under study. The drug aims to promote neuroplasticity, potentially helping patients break negative thought patterns. Researchers caution that results do not prove a permanent cure.

$LLYHighAI 9/10

Eli Lilly (LLY) Finalizes $2.8B AtaiBeckley Acquisition for Depression Treatment Pipeline

Eli Lilly (LLY) completed its $2.8B acquisition of AtaiBeckley (ATAI) on September 11, 2026. AtaiBeckley shareholders received $6.75 per share plus contingent value rights (CVRs) worth up to $2.50 per share. AtaiBeckley shares rose 80% in the six months before the deal, closing at $7.35. The company will delist from Nasdaq. LLY shares closed at $1,119.26, down 0.33%.

$LLYMedAI 9/10

Lilly Completes AtaiBeckley Acquisition to Expand Mental Health Pipeline

Eli Lilly (LLY) completed its acquisition of AtaiBeckley, adding a clinical-stage portfolio of rapid-acting neuroplastogens to its neuroscience pipeline. The deal expands Lilly's focus on treatment-resistant depression and other mental health conditions, with BPL-003 as the lead program. Financial terms were not disclosed.

$LLYMedAI 8/10

Share AtaiBeckley Buyout – Minichart

Eli Lilly completed its $6.75-per-share acquisition of AtaiBeckley Inc., taking the company private. Shareholders received $6.75 in cash plus contingent value rights (CVRs) worth up to $2.50 more if milestones are met. AtaiBeckley's stock will be delisted from Nasdaq.